肝脏纤维化的血清学标志物检测的现状和展望  

The detection and clinical application of serologic biomarkers for liver fibrosis, the present and future perspectives

作　　者：沈立松[1] 周韵斓[1] 

机构地区：[1]上海交通大学医学院附属新华医院检验科,200092

出　　处：《中华检验医学杂志》2014年第2期93-95,共3页Chinese Journal of Laboratory Medicine

摘　　要：肝脏纤维化是各种慢性肝病所致的肝脏损伤的共同通路。它的非侵入性评估方法方便易行，便于疾病动态监测，具有临床应用价值。肝纤维化的血清学标志物包括反映细胞外基质生成的直接标志物和体现肝脏合成、代谢、储备功能的间接标志物。各种综合血清学标志物评估模型可确定显著性纤维化和肝硬化，减少不必要的肝脏穿刺活检，可辅助疾病的诊断分期、预后评估、治疗监测。现有的血清学标志物检测平台和试剂的分析性能具有较大的差异，检测的标准化将有助于提高结果的可比性。大规模、多中心的临床验证研究对推广适合中国慢性肝病人群的综合血清标志物评估模型非常必要。（中华检验医学杂志，2014，37：93—95）Hepatic fibrosis is the final common pathway for liver injury caused by various chronic liver diseases. Noninvasive assessments of liver fibrosis are valuable in clinical use since they are easy to apply and monitor disease progression. Serologic biomarkers for liver fibrosis consist of direct markers which reflect ECM turnover and indirect markers which show liver function of synthesis, metabolism and reservation. A number of assessment models can identify significant fibrosis and cirrhosis, and avoid unnecessary liver biopsy. They can be used for disease staging, prognosis prediction, and treatment surveillance. Variation of analytical performances exists among diverse analyzers and assays. The standardization of these tests will enhance their comparability. Large scale and muhicenter clinical verification studies are needed for the clinical utility of these assessment models based on Chinese population of chronic hepatic diseases. （Chin J Lab Med,2014,37：93-95）

关 键 词：肝硬化 细胞外基质 生物学标记 

分 类 号：R575[医药卫生—消化系统] R446.1[医药卫生—内科学]